FCC 5Alternative Names: 2-N-carboxamidinonormianserin
Latest Information Update: 30 May 2001
At a glance
- Originator Monash University
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antidepressants; Dibenzazepines; Small molecules
- Mechanism of Action Histamine H1 receptor antagonists; Serotonin receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Allergic asthma